Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02201251 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate the Safety of the Drugs Topiramate and Levetiracetam in Treating Children Recently Diagnosed With Epilepsy
A Phase 3 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 63
- Enrollment target
NCT02201251 is a Phase 3 study that has completed, run by Janssen Research & Development. The registered enrollment target is 63 participants.
The verdict
NCT02201251, a Phase 3 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 63 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of topiramate monotherapy compared with levetiracetam another standard antiepileptic drug (AED), as monotherapy for new-onset or recent-onset epilepsy (seizure disorder) on pediatric growth and maturation, bone mineralization, and kidney stone formation in children aged 2 to 15 years.
Interventions
- DRUG Levetiracetam
- DRUG Topiramate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2014-10-06 |
| Est. Completion | 2020-04-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02201251
The ClinicalTrials.gov registry entry for NCT02201251 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Levetiracetam is the first listed.
NCT02201251 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02201251 about?
NCT02201251 is a clinical study titled "A Study to Investigate the Safety of the Drugs Topiramate and Levetiracetam in Treating Children Recently Diagnosed With Epilepsy". The purpose of this study is to evaluate the safety of topiramate monotherapy compared with levetiracetam another standard antiepileptic drug (AED), as monotherapy for new-onset or recent-onset epilepsy (seizure disorder) on pediatric growth and maturation, bone mineralization, and kidney stone form...
What is the current status of trial NCT02201251?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 63 participants. The study started on 2014-10-06. Estimated completion is 2020-04-30.
What interventions are being tested in trial NCT02201251?
The interventions under investigation include: Levetiracetam (DRUG), Topiramate (DRUG).
Who is sponsoring clinical trial NCT02201251?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.